ABM Industries' ABMRC Raises $14.8 Million for Innovative Airway Clearance Solutions
- ABM Respiratory Care raises $14.8 million in Series B financing, exceeding its $12 million goal.
- Funding will support the commercialization of BiWaze® Clear, an advanced airway clearance system for hospitals and homes.
- ABMRC aims to enhance patient care and set new standards in respiratory therapies with its innovative solutions.
ABM Respiratory Care Secures $14.8 Million to Advance Innovative Airway Clearance Solutions
ABM Respiratory Care (ABMRC), a leader in medical technology specializing in airway clearance and ventilation solutions, successfully concludes its Series B financing round, raising an impressive $14.8 million. This funding surpasses the initial goal of $12 million, reflecting strong investor confidence in the company’s vision and operational success. The round is led by Peter Soderberg, ABMRC's Chairman and Managing Partner of Worthy Venture Resources, LLC, who significantly increases his own investment in recognition of the company’s promising trajectory. Other notable participants include Blue Wave Capital, LLC, alongside various investors committed to advancing innovations in respiratory care.
The newly acquired funding is earmarked for expanding access to ABMRC’s cutting-edge respiratory therapy platform, which is poised to transform the care landscape for individuals grappling with respiratory challenges. CEO Greg Miller asserts that this financial boost will facilitate the commercialization of BiWaze® Clear, the company’s latest airway clearance system. Designed for both hospital and home environments, BiWaze® Clear combines lung expansion, high-frequency oscillations, and aerosol delivery into a compact, battery-operated device. This innovative technology aims to enhance lung function by promoting effective mucus clearance and optimizing aerosol deposition deep within the lungs, ultimately leading to shorter therapy sessions and improved patient usability.
Soderberg emphasizes that his enhanced investment stems from ABMRC’s strong performance and execution with its initial devices. The company is dedicated to developing intelligent and clinically differentiated respiratory care solutions aimed at improving oxygen exchange, minimizing aerosol emission exposure, and fostering better disease management. With this funding, ABMRC marks a significant milestone in its mission to globally impact patient care and enhance the quality of life for individuals suffering from respiratory ailments.
In addition to the funding announcement, ABMRC's commitment to innovation in respiratory care reflects a growing trend within the medical technology sector. As healthcare systems increasingly prioritize effective and user-friendly solutions, companies like ABMRC are positioned to play a vital role in shaping the future of respiratory therapies. The focus on creating devices that cater to both hospital and home use underscores the importance of accessibility and efficiency in patient care.
As ABMRC moves forward with its expansion plans, the company not only aims to enhance its product offerings but also to set new standards in respiratory care. The successful completion of the Series B round highlights the potential for innovative solutions to address the pressing needs of patients and healthcare providers alike.